Roche today announces that its drug candidate for Haemophilia A has reached its primary endpoint in the phase III HAVEN 1 study, as well as all secondary endpoints.

Roche (OTCQX:RHHBY) today announces that its drug candidate for Haemophilia A has reached its primary endpoint in the phase III HAVEN 1 study, as well as all secondary endpoints.
According to the press release:

“The study showed a statistically significant reduction in the number of bleeds over time in people treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment.”

Sandra Horning, Roche’s Chief Medical Officer, said the following:

“We are pleased to see that, in our first pivotal trial, emicizumab prophylaxis significantly reduced the number of bleeds over time in people in this difficult-to-treat setting. We look forward to working with health authorities to bring this treatment to the haemophilia community as soon as possible.”

Read the full press release here.

drug candidate endpoint endpoints haemophilia health phase iii roche Company News